Analysis of R&D and SG&A Expense Ratios and Dependence on Generic Drugs
"Some Companies May Experience Only Typical Market Fluctuations"

As the pharmaceutical industry pushes back against the government's plan to lower the prices of generic drugs, warning of potential losses of up to 3 trillion won, it has been confirmed that the Ministry of Health and Welfare has begun quantitatively analyzing the impact of price cuts on individual pharmaceutical companies. The Ministry is reportedly sharing preliminary internal findings indicating that the scale of losses resulting from the price reduction policy will be much smaller than the industry's claims.


According to government and industry sources on January 30, this analysis was conducted on selected pharmaceutical companies based on the drug pricing system reform plan announced in November of last year. During the analysis, key variables included each company's ratio of research and development (R&D) and selling, general, and administrative (SG&A) expenses to sales, as well as their dependence on generic drugs. The analysis compares the number of products subject to price cuts for each company and the resulting decrease in sales.

"Losses Lower Than Industry Fears"... Health Ministry Conducts Company-by-Company Analysis of Drug Price Cuts View original image

The Ministry of Health and Welfare explained that, rather than evaluating the entire pharmaceutical market with a single figure, it is examining the impact of the price reduction according to the structure of each company. The Ministry believes that companies with a low dependence on generic drugs and a higher proportion of improved or independently developed new drugs may experience only limited effects from the price cuts. In some cases, the decrease in sales due to the price reductions may be comparable to normal market fluctuations.


An official from the Ministry stated, "It does not appear that the scale of losses will reach the 3 trillion won level cited by the industry," adding, "Based on the reform plan announced in November, we estimate the figure to be around 1 trillion won." The official also noted, "Since the analysis results are not yet finalized, the calculated figures may change going forward."


The government is pursuing a reform of the drug pricing system that includes lowering the pricing ratio for generic drugs from the current 53% level to the 40% range. The goal is to improve the efficiency of the National Health Insurance budget and normalize the drug pricing structure. The pharmaceutical industry is strongly opposing the policy, arguing that its implementation could lead to significant sales losses and a contraction in R&D across the entire sector.


The industry estimates that the losses from the price cuts could reach up to 3 trillion won. The Emergency Committee for Drug Pricing System Reform, which includes the Korea Pharmaceutical and Bio-Pharma Manufacturers Association and other industry groups, held a press conference last month, claiming that if the government's plan to lower generic drug prices is implemented, the industry could face losses of up to 3.6 trillion won. The industry warns that this would inevitably trigger a chain reaction of reduced R&D, job cuts, and decreased investment in facilities.



In political circles, particularly among the ruling party, there is a strong sentiment that a more detailed analysis is needed to determine the specific extent of the impact of the price cuts and the credibility of the industry's claims. An official from the office of Democratic Party lawmaker Kim Yoon, a member of the National Assembly's Health and Welfare Committee, stated, "Even with the same decrease in sales, the burden may be felt differently by companies that invest in R&D compared to those focused on sales and marketing," and added, "A simple sales decline rate alone is not sufficient to fully explain impacts such as reduced R&D or setbacks in new drug development." Kim's office is also considering securing the raw data from the Ministry's initial analysis for its own independent review.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing